Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2009, Vol. 7 ›› Issue (4): 306-308.doi: 10.3736/jcim20090402

• Original Clinical Research • Previous Articles     Next Articles

Thinking on syndrome differentiation treatment and personalized therapy for tumor

Jing Li   

  1. Department of Traditional Chinese Medicine, the Fourth Hospital, Hebei Medical University, Shijiazhuang 050011,Hebei Province, China
  • Received:2008-12-04 Accepted:2009-02-04 Online:2009-04-20 Published:2009-04-15

The concepts of Western medicine in treating tumor have changed markedly in recent years, and begun to put more emphasis on the whole survival status of patients. With recent emergence of targeted drugs, it was found that curative effects of the same targeted drugs in treating patients with the same tumor type even the same tumor pathological subtype but different therapeutic targets may be different. On the contrary, the curative effects of different targeted drugs in treating patients with different tumor types but the same therapeutic targets may be similar. Accordingly, the viewpoint of personalized therapy is advocated in Western medicine. Under the guidance of syndrome differentiation treatment in traditional Chinese medicine (TCM), patients with the same tumor and different syndromes should be treated by different herbs, and patients with different tumor and the same syndrome should be treated by the same herbs. Both the theories of "the same treatment for the same syndrome" and "the same treatment for the same therapeutic target" indicate that personalized therapy in Western medicine is similar to TCM syndrome differentiation treatment. The article focuses on "different treatments for the same disease" as well as "the same treatment for different diseases" to describe the similar points between personalized therapy and TCM syndrome differentiation treatment and thereby proves that TCM syndrome differentiation treatment is a scientific and essential approach in treating tumor. At the same time, the article also points out the problems and solution methods of TCM syndrome differentiation treatment.

Key words: Syndrome differentiation treatment, Personalized therapy, Neoplasms, Traditional Chinese medicine

[1] Zhang XY, Xu LY, Wang H, Zhu YZ, Liu Z, Yue WT, Tang JF, Wu W, Liu Z, Wu YH, Zhang CY, Shi YK, Wang MZ, Shi HL, Li MZ, Meng QY, Guo LL, Wang JH, Li XB . The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced non-small-cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2008,11(2):206-213
张新勇, 徐丽艳, 汪惠, 朱允中, 刘喆, 岳文涛, 唐俊舫, 武玮, 刘赞, 吴羽华, 张春彦, 石远凯, 王孟昭, 史鹤玲, 李明智, 孟弃逸, 郭丽丽, 王敬慧, 李雪冰 . EGFR基因突变与酪氨酸激酶抑制剂疗效及预后之间的关系[J]. 中国肺癌杂志, 2008,11(2):206-213
[2] Liu YF, Guan XX, Chen LB, Chen YT . Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2008,15(17):1285-1288
柳艳飞, 管晓翔, 陈龙邦, 陈一天 . ERCC1与XPD和XPA的遗传多态性对非小细胞肺癌铂类化疗敏感性预测的研究[J]. 中华肿瘤防治杂志, 2008,15(17):1285-1288
[3] Meng FY, Zheng WY, Liu XL, Song LL, Xu B, Zhang Y . Clinical observation of curative effects of imatinib in treatment of 26 cases of chronic myeloid leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2004,25(5):314-315
孟凡义, 郑维扬, 刘晓力, 宋兰林, 徐兵, 张钰 . 伊马替尼治疗慢性粒细胞白血病26例临床观察[J]. 中华血液学杂志, 2004,25(5):314-315
[4] Xu WT, Li R . Efficacy of imatinib mesylate in treatment of advanced gastrointestinal stromal tumors[J]. Di Er Jun Yi Da Xue Xue Bao, 2005,26(5):583-584
徐文通, 李荣 . 甲磺酸伊马替尼治疗晚期胃肠道恶性间质瘤疗效的初步观察[J]. 第二军医大学学报, 2005,26(5):583-584
[5] Ma D . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. Xun Zheng Yi Xue, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007
马冬 . 贝伐单抗联合依立替康、氟尿嘧啶/甲酰四氢叶酸对转移性结直肠癌的治疗[J]. 循证医学, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007
[6] Wang T, Luo LL . A systematic review of bevacizumab for non-small cell lung cancer[J]. Zhongguo Shi Yong Yi Yao, 2008,3(5):1-2
王艇, 罗黎力 . 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008,3(5):1-2
[1] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[2] Xue-qing Yu, Shu-guang Yang, Yang Xie, Jian-sheng Li. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of exploratory trial. Journal of Integrative Medicine, 2020, 18(2): 163-168.
[3] Chang-quan Ling. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). Journal of Integrative Medicine, 2020, 18(2): 87-88.
[4] Wen Qiang Lee, Jeremy Teoh, Pei Zheng Kenneth Lee, Zhi Xiong Gerard Low, Xueling Sim, Foong Fong Mary Chong, Norbert Ludwig Wagner. Factors influencing communication of traditional Chinese medicine use between patients and doctors: a multisite cross-sectional study. Journal of Integrative Medicine, 2019, 17(6): 396-403.
[5] Mikhail Teppone. Medicine has always been “Modern” and “Scientific” from ancient times to the present day. Journal of Integrative Medicine, 2019, 17(4): 229-237.
[6] Charles Dalcanale Tesser, Ari Ojeda Ocampo Moré, Melissa Costa Santos, Emiliana Domingues Cunha da Silva, Fátima Terezinha Pelachini Farias, Lúcio José Botelho. Auriculotherapy in primary health care: A large-scale educational experience in Brazil. Journal of Integrative Medicine, 2019, 17(4): 302-309.
[7] Rachael Farrington, Ian F.Musgrave, Roger W.Byard. Evidence for the efficacy and safety of herbal weight loss preparations. Journal of Integrative Medicine, 2019, 17(2): 87-92.
[8] Fung-Kei Cheng. An overview of the contribution of acupuncture to thyroid disorders. Journal of Integrative Medicine, 2018, 16(6): 375-383.
[9] Chang-quan Ling, Jia Fan, Hong-sheng Lin, Feng Shen, Zhen-ye Xu, Li-zhu Lin, Shu-kui Qin, Wei-ping Zhou, Xiao-feng Zhai, Bai Li, Qing-hui Zhou, on behalf of the Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. Journal of Integrative Medicine, 2018, 16(4): 236-248.
[10] Xuan Liu, Li-juan Xiu, Jian-peng Jiao, Jing Zhao, Ying Zhao, Ye Lu, Jun Shi, Yong-jin Li, Min Ye, Yu-fang Gu, Xiao-wei Wang, Jing-yu Xu, Ci-an Zhang, Yong-ying Liu, Yun Luo, Xiao-qiang Yue. Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: A retrospective clinical analysis. Journal of Integrative Medicine, 2017, 15(6): 469-475.
[11] Jesmin Mondal, Asmita Samadder, Anisur Rahman Khuda-Bukhsh. Psorinum 6× triggers apoptosis signals in human lung cancer cells. Journal of Integrative Medicine, 2016, 14(2): 143-153.
[12] Qing Ji, Yun-quan Luo, Wen-hai Wang, Xuan Liu, Qi Li, Shi-bing Su. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine, 2016, 14(1): 12-21.
[13] Qing-qing Zang, Lu Zhang, Ning Gao, Cheng Huang. Ophiopogonin D inhibits cell proliferation, causes cell cycle arrest at G2/M, and induces apoptosis in human breast carcinoma MCF-7 cells. Journal of Integrative Medicine, 2016, 14(1): 51-59.
[14] Bing He, Ge Zhang, Ai-ping Lu. Integrative network analysis: Bridging the gap between Western medicine and traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(3): 133-135.
[15] Xuanbin Wang, Ning Wang, Fan Cheung, Lixing Lao, Charlie Li, Yibin Feng. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. Journal of Integrative Medicine, 2015, 13(3): 142-164.
Full text



[1] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[2] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[3] Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5] Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[7] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[8] Liang-ping Hu , Xiao-lei Bao, Xue Guan. Statistical inference and experimental design of univariate qualitative data of single-group design. Journal of Chinese Integrative Medicine, 2010, 8(11): 1085-1089
[9] Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[10] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205